Bio-Techne Corporation has released its third-quarter fiscal 2026 results, reporting sales of US$311.42 million and net income of US$51.05 million, alongside higher basic and diluted earnings per ...

Shares of Bio-Techne Corp. advanced 7.39% to $50.91 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.38% to 7,337.11 and Dow ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

The company's 10-K for fiscal year 2024 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

May 6 (Reuters) - Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

For more information on Bio-Techne and its brands, please visit or follow the company on social media at LinkedIn , X , or YouTube . Forward Looking Statements: Our press releases may contain forward ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...